Potashnick Robert 4

What Happened
Robert Potashnick, Interim Chief Financial Officer of Envoy Medical, was granted a derivative award covering 15,000 shares on 2026-02-05. The Form 4 reports an acquisition of 15,000 shares at $0.00 (derivative), reflecting an option/award grant rather than a cash purchase or sale.

Key Details

• Transaction date: 2026-02-05 (reported on Form 4 filed 2026-02-09).
• Transaction type/code: Award/Grant (A), derivative; 15,000 shares reported at $0.00.
• Vesting (footnote): Options to purchase 3,750 shares vest on 2/5/2027, then 11,250 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months (one-year partial cliff then monthly vesting).
• Shares owned after transaction: not disclosed in this filing.
• Filing timeliness: Filed on 2026-02-09 for a 2026-02-05 transaction (within the Form 4 two-business-day reporting window).

Context
This was a derivative award (options) with a multi-year vesting schedule — no immediate sale or cash exercise occurred. Such grants are common as compensation and do not by themselves indicate an insider buying or selling shares; they simply provide the right to acquire shares in the future subject to vesting and any exercise price/terms.